ArticleFrontiers in oncology2026
Exploring the clinical value of quantitative ultrasound scoring method in optimizing the classification of breast BI-RADS category 4a nodules in the Tibetan Plateau region.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the clinical utility of a quantitative ultrasound (US) scoring method in refining the classification of Breast Imaging Reporting and Data System (BI-RADS) Class 4a breast nodules in patients from the Tibetan Plateau region. Methods: A retrospective analysis was conducted on the US and contrast-enhanced US (CEUS) imaging characteristics of 275 breast nodules from high-altitude regions. Significant US features were identified and assigned scores using chi-square tests and binary logistic regression analysis. Separate scores for each nodule were calculated based on US and CEUS findings. Receiver operating characteristic curves were generated to determine the optimal cutoff value, which served as the basis for classification refinement. Nodules with scores below the cutoff value were reclassified as Category 3, while those with one or more scores meeting or exceeding the cutoff value remained in Category 4a. The differences in biopsy rates and malignant detection rates for Category 4a nodules were assessed before and after applying the optimized classification system. Results: All 275 nodules were pathologically confirmed, with 148 classified as benign and 127 as malignant. Regression analysis of US features revealed significant differences between benign and malignant nodules regarding the boundary, morphology, internal echo, resistance index, and hyperechoic halo ( Conclusion: Quantitative US scoring serves as an effective index for optimizing the classification of BI-RADS Category 4a breast nodules in high-altitude regions. This method enhances diagnostic accuracy, significantly reduces unnecessary biopsy procedures, and provides a reliable framework for precise clinical diagnosis and treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.